Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?

Publisher： Bentham Science Publishers

E-ISSN： 2212-3970|5|1|22-28

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.5, Iss.1, 2010-01, pp. : 22-28

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipid Rafts and Fas/CD95 Signaling in Cancer Chemotherapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 6, Iss. 3, 2011-09 ,pp. : 274-283

Bentham Science Publishers

Access to resources Recommend Favorite

Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression

By Caruso Joseph  

Clinical and Experimental Metastasis, Vol. 28, Iss. 6, 2011-08 ,pp. : 529-540

Springer Publishing Company

Access to resources Recommend Favorite

Lipid rafts, death receptors and CASMERs: new insights for cancer therapy

By Mollinedo Faustino   Gajate Consuelo  

Future Oncology, Vol. 6, Iss. 4, 2010-04 ,pp. : 491-494

Future Medicine

Access to resources Recommend Favorite

Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells

By                  

International Journal of Oncology, Vol. 42, Iss. 2, 2013-01 ,pp. : 699-711

Spandidos Publications

Access to resources Recommend Favorite

Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer

By                    

International Journal of Oncology, Vol. 40, Iss. 3, 2012-01 ,pp. : 645-654

Spandidos Publications

Access to resources Recommend Favorite